人肝细胞肝癌MHCC97H裸鼠移植模型的建立及索拉菲尼的药效研究  

Establishment of Human Hepatocellular Carcinoma Cell MHCC97H Xenografts in BALB/c Nude Mice and Evaluation of Sorafenib in MHCC97H Xenografts

作　　者：杨璐[1] 吴燕华[1] 

机构地区：[1]复旦大学生命科学学院,上海200438

出　　处：《中国细胞生物学学报》2016年第9期1084-1090,共7页Chinese Journal of Cell Biology

基　　金：上海市教委"晨光"计划(批准号:12CG03);复旦大学"卓学计划"资助的课题~~

摘　　要：索拉菲尼是靶向血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)、B-Raf原癌基因(B-Raf proto-oncogene)等多种酪氨酸激酶的抑制剂,能有效延长晚期肝细胞肝癌(简称肝癌)患者的生存时间。该研究利用人肝癌细胞MHCC97H成功建立了裸鼠皮下异位移植模型以及原位移植模型,并评估了索拉菲尼对MHCC97H移植瘤的治疗作用。结果表明,MHCC97H可以在裸鼠皮下形成异位移植瘤,每天灌胃30 mg/kg索拉菲尼可显著抑制肿瘤生长。同时,MHCC97H也可以在裸鼠肝脏形成原位移植瘤。每天灌胃30 mg/kg索拉菲尼可以显著抑制裸鼠的血清甲胎蛋白(alpha fetoprotein,AFP)水平及原位瘤生长。综上所述,MHCC97H是构建皮下异位移植以及原位移植模型的一个理想肝癌细胞系,灌胃索拉菲尼在这两种移植瘤模型中都表现出显著的肿瘤抑制效果。Sorafenib, the inhibitor of multiple tyrosine kinase including vascular endothelial growth factor receptor（VEGFR） and B-Raf, can effectively prolong the survival time of patients with advanced liver cancer. Our study successfully established human hepatocellular carcinoma cell MHCC97 H subcutaneous and orthotopic xenograft models in BALB/c nude mice, and further evaluated the therapeutic effect of sorafenib on the 2 xenograft models. Our results showed that MHCC97 H cells grew well after subcutaneously transplanted into BALB/c nude mice. Sorafenib in 30 mg/kg per os（p.o.） daily significantly inhibited tumor growth. Moreover, MHCC97 H cells could also form orthotopic xenografts in the liver of BALB/c nude mice. Sorafenib in 30 mg/kg p.o. daily signifi-cantly reduced the AFP level in serum and suppressed tumor growth in mice liver. In conclusion, MHCC97 H is an ideal liver cancer cell line in establishment of subcutaneous and orthotopic xenografts models. Sorafenib showed significant anti-tumor effect on the 2 xenograft models.

关 键 词：索拉菲尼 MHCC97H 异位皮下移植模型 原位移植模型 

分 类 号：R735.7[医药卫生—肿瘤] R-332[医药卫生—临床医学]